Argireline (Acetyl Hexapeptide-3)
Synthetic hexapeptide modeled on the SNAP-25 N-terminus. Topical-only botulinum-mimetic — partially inhibits neurotransmitter release at the neuromuscular junction underneath thin skin (forehead, periorbital), softening expression-line depth.
How it clearsHalf cleared in ~8h. Most (~96%) gone by ~2d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
Lipotec (now Lubrizol) developed the molecule in 2001. Marketed as a topical 'needle-free Botox' in mass-market cosmetics. Real efficacy is far below injectable BoNT-A — Blanes-Mira 2002 + several cosmetic-trial replications show ~10-30% wrinkle-depth reduction over 28-day daily-use protocols, modest vs the 70-90% effect of injectable Botox. Bioavailability through intact stratum corneum is the long-standing question — penetration enhancers + niosome encapsulation are formulation tricks vendors lean on. Stack catalogs Argireline because it is the highest-volume cosmetic peptide in consumer skincare and biohackers + dermatology-curious cohorts cycle it; do NOT confuse with injectable Botox.
Real effect is modest vs injectable Botox — manage expectations. Penetration through stratum corneum is the bioavailability question; many drugstore formulations contain trace levels that may not reach the neuromuscular junction. Avoid use near eyes / mucosa. Not a substitute for botulinum-toxin injection if that's what the user actually wants.
Upload your data to see how it relates to Argireline.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Argireline (Acetyl Hexapeptide-3) — primary mechanism: synthetic hexapeptide modeled on the snap-25 n-terminus. topical-only botulinum-mimetic — partially inhibits neurotransmitter release at the neuromuscular junction underneath thin skin (forehead, periorbital), softening expression-line depth.
2 supporting referencesVerified 13d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Cosmetic-ingredient classification (US/EU/MX) — no FDA drug pathway · widely sold OTC at consumer-cosmetic tier
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.